ReviewJournal of clinical medicine2021
Treatment of Glaucoma Patients with Flammer Syndrome.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Cold Extremities and Underweight as a Combined Risk Profile for Open-Angle Glaucoma: A Population-Based Cross-Sectional Study in Korea.Medicina (Kaunas, Lithuania) · 2026Article
- Disease Diagnosis Using Retinal Vasculature: Insights from Flammer Syndrome and AI.Brain sciences · 2025Review
- [Glaucoma Patient with Suspected Flammer Syndrome: Diagnostic Procedures and Therapeutic Implications].Klinische Monatsblatter fur Augenheilkunde · 2024Review
- Unveiling the silent link: Normal-tension glaucoma's enigmatic bond with cardiac blood flow.World journal of cardiology · 2024Review
- Pharmaceutical Approaches to Normal Tension Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Role of ocular blood flow in normal tension glaucoma.Advances in ophthalmology practice and researchReview
- Ocular and Systemic Factors Associated with Glaucoma.Journal of current glaucoma practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flammer syndrome (FS) describes a phenotype characterized by the presence of primary vascular dysregulation along with a number of symptoms and signs. Although most people with FS are healthy, FS favors the occurrence of certain diseases, such as normal tension glaucoma. This is because disturbed autoregulation makes the eye more sensitive to intraocular pressure (IOP) spikes or blood pressure drops. Treatment of FS is generally appropriate when patients either suffer greatly from their symptoms or if we can assume that it has contributed to a disease. In glaucoma, this may be the case if the glaucoma damage progresses despite well-controlled IOP. Both the still sparse scientific studies and our long clinical experience suggest that FS-targeted therapy not only relieves the symptoms of FS but also slows the progression of glaucoma damage in selected cases. This description is intended not only to help affected patients but to also motivate clinicians and researchers to conduct therapy studies to confirm or refute our observations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.